SCHEMBL3544218

SCHEMBL3544218

CCCCCCc1cc(C(=O)O)cc(OC)c1OC

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 10/20 0.58
PPARA Q07869 2/20 0.53
TPMT P51580 1/20 0.53
PPARG P37231 1/20 0.50
PTGS2 P35354 3/20 0.48
PLA2G2A P14555 1/20 0.47
ECE1 P42892 1/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA3 P07451 1/20 0.46
PKM P14618 1/20 0.46
CA4 P22748 1/20 0.46
CA6 P23280 1/20 0.46
CA5A P35218 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
CA5B Q9Y2D0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3547398 0.99 ALOX5 (0.57) ALOX5PPARATPMTPPARGPTGS2
SCHEMBL3546481 0.94 TPMT (0.55) ALOX5PPARATPMTPPARGPTGS2
SCHEMBL3546860 0.88 TPMT (0.58) ALOX5PPARATPMTPPARGPTGS2
SCHEMBL3547720 0.87 ALOX5 (0.56) ALOX5PTGS2
SCHEMBL3547886 0.86 ALOX5 (0.56) ALOX5PTGS2
SCHEMBL3547228 0.85 TPMT (0.55) ALOX5TPMTPTGS2CA12CA1
SCHEMBL3543507 0.85 TPMT (0.49) ALOX5PPARATPMTPTGS2CA12
SCHEMBL3547394 0.84 TPMT (0.54) ALOX5TPMTPTGS2CA12CA1
SCHEMBL3550240 0.84 TPMT (0.54) ALOX5TPMTPTGS2CA12CA1
SCHEMBL3547586 0.83 TPMT (0.50) ALOX5TPMTPTGS2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE ALOX5 3812/4885PPARA 3704/4885TPMT 3495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.